{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:26:28Z","timestamp":1789255588967,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40487-019-0094-x","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T03:17:31Z","timestamp":1556335051000},"page":"67-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"7","author":[{"given":"L. Elise","family":"Horvath Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik J.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"issue":"1","key":"94_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"94_CR2","unstructured":"NIH. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML). https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 10 Oct 2018."},{"key":"94_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"94_CR4","first-page":"1","volume":"6","author":"AM Almeida","year":"2016","unstructured":"Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1\u20137.","journal-title":"Leuk Res Rep."},{"key":"94_CR5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","volume":"97","author":"B Oran","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916\u201324.","journal-title":"Haematologica"},{"issue":"18","key":"94_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909\u201318.","journal-title":"N Engl J Med"},{"issue":"12","key":"94_CR7","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","volume":"116","author":"S Abbas","year":"2010","unstructured":"Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122\u20136.","journal-title":"Blood"},{"issue":"14","key":"94_CR8","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","volume":"28","author":"G Marcucci","year":"2010","unstructured":"Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348\u201355.","journal-title":"J Clin Oncol"},{"issue":"22","key":"94_CR9","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","volume":"28","author":"P Paschka","year":"2010","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636\u201343.","journal-title":"J Clin Oncol"},{"issue":"8","key":"94_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol. 2017;18(8):1061\u201375.","journal-title":"Lancet Oncol."},{"key":"94_CR11","unstructured":"Shaffer AT, Broderick JM. The first targeted therapy directed at FLT3 mutations in patients with AM. 2017. http:\/\/www.targetedonc.com\/publications\/targeted-therapy-news\/2017\/july-2017\/the-first-targeted-therapy-directed-at-flt3-mutations-in-patients-with-aml. Accessed 2 Mar 2018."},{"issue":"16","key":"94_CR12","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","volume":"24","author":"T Buchner","year":"2006","unstructured":"Buchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16):2480\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"94_CR13","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70\u00a0years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20139.","journal-title":"Blood"},{"issue":"4","key":"94_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.leukres.2011.12.019","volume":"36","author":"GJ Roboz","year":"2012","unstructured":"Roboz GJ, Wissa U, Ritchie EK, et al. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res. 2012;36(4):407\u201312.","journal-title":"Leuk Res"},{"key":"94_CR15","unstructured":"National Comprehensive Cancer Network. Acute Myeloid Leukemia (Version 1.2018). http:\/\/www.nccn.org\/guidelines\/aml\/files\/assets.pdf. Accessed 5 Feb 2018."},{"issue":"4","key":"94_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13670-017-0227-8","volume":"6","author":"S Storey","year":"2017","unstructured":"Storey S, Gray TF, Bryant AL. Comorbidity, physical function, and quality of life in older adults with acute myeloid leukemia. Curr Geriatr Rep. 2017;6(4):247\u201354.","journal-title":"Curr Geriatr Rep."},{"issue":"1","key":"94_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0305-7372(03)00142-7","volume":"30","author":"A Redaelli","year":"2004","unstructured":"Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev. 2004;30(1):103\u201317.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"94_CR18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-Specific Programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"94_CR19","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"94_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes."},{"key":"94_CR21","unstructured":"Health Information Technology for Economic and Clinical Health (HITECH) Act. https:\/\/www.healthit.gov\/policy-researchersimplementers\/health-it-legislation-and-regulations. Accessed 1 Mar 2018."},{"key":"94_CR22","unstructured":"Health Insurance Portability and Accountability Act of 1996 (HIPAA). https:\/\/www.hhs.gov\/hipaa\/for-professionals\/index.html. Accessed 1 Mar 2018."},{"issue":"8","key":"94_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","volume":"15","author":"D Cella","year":"2012","unstructured":"Cella D, Jensen SE, Webster K, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire. Value Health. 2012;15(8):1051\u20138.","journal-title":"Value Health."},{"issue":"3","key":"94_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cncr.31082","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124(3):587\u201395.","journal-title":"Cancer"},{"issue":"4","key":"94_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012;36(4):438\u201342.","journal-title":"Leuk Res"},{"issue":"3","key":"94_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"11","key":"94_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"6","key":"94_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523\u201332.","journal-title":"Qual Life Res"},{"key":"94_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 1","key":"94_CR30","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","volume":"8","author":"L Abetz","year":"2005","unstructured":"Abetz L, Coombs JH, Keininger DL, et al. Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health. 2005;8(Suppl 1):S41\u201353.","journal-title":"Value Health"},{"issue":"1","key":"94_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11136-015-1062-z","volume":"25","author":"K Cheung","year":"2016","unstructured":"Cheung K, de Mol M, Visser S, Den Oudsten BL, Stricker BH, Aerts JG. Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer. Qual Life Res. 2016;25(1):71\u201380.","journal-title":"Qual Life Res"},{"issue":"1","key":"94_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"5","key":"94_CR33","first-page":"1437","volume":"26","author":"N Kayastha","year":"2018","unstructured":"Kayastha N, Wolf SP, Locke SC, Samsa GP, El-Jawahri A, LeBlanc TW. The impact of remission status on patients\u2019 experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data. Support Care Cancer. 2018;26(5):1437\u201345.","journal-title":"Support Care Cancer"},{"issue":"10","key":"94_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CEOR.S153286","volume":"25","author":"A Forsythe","year":"2018","unstructured":"Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G. Systematic review of health state utility values for acute myeloid leukemia. Clinicoeconomics Outcomes Res. 2018;25(10):83\u201392.","journal-title":"Clinicoeconomics Outcomes Res."},{"issue":"9","key":"94_CR35","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2015.137","volume":"50","author":"S Kurosawa","year":"2015","unstructured":"Kurosawa S, Yamaguchi T, Mori T, et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant. 2015;50(9):1241\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"94_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40487-016-0039-6","volume":"5","author":"EE Korol","year":"2017","unstructured":"Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van Nooten F. Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review. Oncol Ther. 2017;5(1):1\u201316.","journal-title":"Oncol Ther."},{"issue":"8","key":"94_CR37","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","volume":"24","author":"T Atkinson","year":"2016","unstructured":"Atkinson T, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669\u201376.","journal-title":"Support Care Cancer"},{"issue":"Suppl 31","key":"94_CR38","first-page":"43","volume":"35","author":"A El-Jawahri","year":"2017","unstructured":"El-Jawahri A. Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia. J Clin Oncol. 2017;35(Suppl 31):43.","journal-title":"J Clin Oncol."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-019-0094-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-019-0094-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-019-0094-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:59:58Z","timestamp":1724457598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-019-0094-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1007\/s40487-019-0094-x","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}